The resistance of the Hh pathway to vitamin D3 treatment may be due to the presence of point mutations in Smo that were shown to prevent the binding of 3β-hydroxysteroids and small molecule inhibitors of the Hh pathway in basal cell carcinoma (BCC) [9]. Here, SMO is linked to basal cell carcinoma.